Over Treatment Radionuclide Therapy (PRRT) of Metastatic Neuroendocrine Neoplasm (NEN) – A Case Report. Abstract #1898

Introduction: Over treatment radionuclide therapy (PRRT) of metastatic neuroendocrine neoplasm (NEN).
Aim(s): A 39-year-old male with NEN G2 of unknown primary site with metastases to liver and bones.
Materials and methods: Since May 2011 patient with abdominal symptoms. CT revealed enlarged liver with metastases. In June 2011 consultation of specimens from metastatic lesions in liver (from laparoscopy) confirmed the diagnosis of NEN G2 Ki-67 uptil 20%. NEN markers and another hormones were in reference values. 68Ga-DOTA-TATE PET/CT scan confirmed the presence of changes with increased expression of somatostatin receptors (SSTR) in the liver and in the skeletal system. Since June 2011 patient has begun treatment with a long-acting somatostatin analogues (SSA). Between 08.2011 and 08.2012 patient received 6 cycles of 90Y/177Lu DOTA-TATE (800 mCi). In April 2013, PET/CT with gallium showed significant regression. In April 2014 PET/CT with gallium showed new foci of increased tracer uptake. In 09.2014 treatment with CAPTEM combined with SSA was commenced. Stereotactic radiosurgery therapy of metastatic changes in brain was carried out (10.2014), but in performed chest CT progression of disease was identified. Between 07.2015 and 02.2016, 4 further cycles of 90Y/177Lu DOTA-TATE treatment were administered (800 mC).
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Karolina Poczkaj

To read results and conclusion, please login ...

Further abstracts you may be interested in

#13 Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic carcinoma
Introduction: Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. At diagnosis, many of them are already advanced and difficult to treat.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#80 Metastatic growth hormone secreting pituitary carcinoma treated with peptide receptor radionuclide therapy
Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#287 Lutetium-177 DOTATATE Therapy in the Management of Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is a specific targeted treatment for NETs expressing somatostatin receptors. 177Lu-DOTATATE is one of several newly available compounds for this treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Giovanni Paganelli